N+1 Brewin, new corporate advisory & brokerage firm formed following the takeover of the Brewin Corporate Advisory & Broking division by N+1, it would add up to 30 people over the next few years to expand its reach.
Chief Executive Jamie Cumming said the firm’s 55-strong workforce would be expanded as it targets new areas.
Cumming said the company had plans to enhance its presence in the diverse sectors such as Information technology and oil & gas.
He added that they would gain a bigger footprint in London, and expand Edinburgh quicker than Glasgow.
Speaking on the topic, Cumming said, "N+1 has indicated they would like to go a bit faster and add up to 30 staff over the next three years. Clearly they would like to have a bigger footprint in London. I think we will expand Edinburgh quicker than Glasgow but we will retain both."
The new business, which established its offices in London, Leeds, Edinburgh, Glasgow and Newcastle, started trading yesterday following an acquisition by management at Brewin Dolphin, with backing from N+1.
N+1 Brewin is now 65 per cent owned by N+1, 21 per cent by the management and 14 per cent by Brewin Dolphin.
In its annual Environmental Responsibility Report for fiscal year 2015 released last Thursday, tech giant Apple has revealed that nearly 90 million pounds of unwanted or broken electronics were processed by the company over the last one year....
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel's...
There was a time just a few years back when Spain ranked second after Greece, as a figure of the euro zone's huge debt crisis and economic slowdown. The country's unemployment climbed to a huge twenty seven percent and the economy was still...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
On Tuesday, tech giant Google released latest to show how much of its online traffic is...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
There are a lot of things not going right at the IRS and...
On Thursday, the US Federal Bureau of Investigation (FBI...
In an announcement made via a blog post on Thursday,...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).